Monitor Phase II trial results in H2 2026 for potential label expansion into CVID and broader PIDs, which could expand leniolisib's addressable market. No immediate trading catalyst from this scientific conference update.
Price Chart
Executive Summary
Pharming announced multiple presentations at the 2026 CIS Annual Meeting, including interim data from a long-term extension study of leniolisib in pediatric APDS patients aged 4-11 and clinical experience data in CVID/CVID-like disorders. The presentations support ongoing Phase II trials in broader primary immunodeficiencies, with results expected in H2 2026. This is a routine scientific update with no material financial data or regulatory catalyst.
Key Facts
- Presentations at CIS 2026 include interim safety/efficacy data from leniolisib long-term extension study in pediatric APDS patients aged 4-11
- Clinical experience data on leniolisib for immune dysregulation in CVID and CVID-like disorders presented
- Two Phase II trials (NCT06897358, NCT06549114) evaluating leniolisib in CVID and PIDs with immune dysregulation are underway
- Results from ongoing Phase II trials expected in second half of 2026
- Leniolisib is already approved for APDS in US, UK, Australia, Israel (ages 12+) and Japan (ages 4+)
- No financial data, revenue, EPS, or guidance provided in the press release
Financial Impact
No financial figures disclosed; impact is limited to potential pipeline expansion signal
Risk Factors
- Phase II trials may fail to meet endpoints, limiting label expansion
- Regulatory reviews in Canada and other countries may be delayed or negative
- Competition from other PI3Kδ inhibitors or alternative therapies
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3289580 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 22, 2026 5w ago | Press Release | — | awaiting T+20 | — | — |
Sep 11, 2026 6w ago | Press Release | — | awaiting T+20 | — | — |
Aug 13, 2026 10w ago | Press Release | — | awaiting T+20 | — | — |
Jul 30, 2026 12w ago | Press Release | — | awaiting T+20 | — | — |
Jul 16, 2026 14w ago | Press Release | — | awaiting T+20 | — | — |
May 28, 2026 21w ago | Press Release | — | awaiting T+20 | — | — |
May 7, 2026 24w ago | Press Release | — | awaiting T+20 | — | — |
May 7, 2026 24w ago | Press Release | — | awaiting T+20 | — | — |
Apr 23, 2026 26w ago | Press Release | — | awaiting T+20 | — | — |
Apr 7, 2026 29w ago | Press Release | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers